Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-12-14
2010-06-29
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07745397
ABSTRACT:
The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
REFERENCES:
patent: 4457917 (1984-07-01), Schaller nee Kornmayer et al.
patent: 4900549 (1990-02-01), De Vries et al.
patent: 5164372 (1992-11-01), Matsuo et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5298246 (1994-03-01), Yano et al.
patent: 5354900 (1994-10-01), Matsuo et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5418219 (1995-05-01), Ueda
patent: 5439688 (1995-08-01), Orsolini et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5716637 (1998-02-01), Anselem et al.
patent: 5733877 (1998-03-01), Sato et al.
patent: 5736519 (1998-04-01), Deigin et al.
patent: 5747653 (1998-05-01), Huergo et al.
patent: 5837500 (1998-11-01), Ladner et al.
patent: 5877155 (1999-03-01), Miller et al.
patent: 5961970 (1999-10-01), Lowell et al.
patent: 6013264 (2000-01-01), Petre et al.
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6372223 (2002-04-01), Kistner et al.
patent: 6406700 (2002-06-01), Srivastava
patent: 6800744 (2004-10-01), Doucette-Stamm et al.
patent: 6833447 (2004-12-01), Goldman et al.
patent: 7329639 (2008-02-01), Hardy et al.
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/11700 (1995-05-01), None
patent: WO 95/19783 (1995-07-01), None
patent: WO 95/20605 (1995-08-01), None
patent: WO 97/11715 (1997-04-01), None
patent: WO 00/06723 (2000-02-01), None
patent: WO 00/58363 (2000-10-01), None
GenCore amino acid database, Accession No. A72330, Jun. 11, 1999.
Hardy, B. et al., “Activation of human lymphocytes by a monoclonal antibody to B lymphoblastoid cells; molecular mass and distribution of binding protein,” Cancer Immunology Immunotherapy, vol. 40, No. 6, 376-382 (1995).
Hardy, B. et al., “Selection of novel peptides-based cancer vaccines by BAT monoclonal antibody,” XP002370959, International Journal of Molecular Medicine, vol. 10, No. Supplement 1, p. S46; 7th World Congress on Advances in Oncology and the 5th International Symposium on Molecular Medicine; Hersonissos, Crete, Greece; Oct. 10-12, 2002.
Nelson et al., “Evidence for lateral gene transfer between Archaea and Bacteria from genome sequence of Thermotoga maritima,” Nature 399: 323-329 (1999).
Raiter, A., “CD4+T lymphocytes as a primary cellular target for BAT mAb stimulation,” International Immunology, vol. 12, No. 11, 1623-1628 (2000).
Ren et al., “Unique physiological and pathogenic features of Leptospira interrogans revealed a whole-genome sequencing,” Nature 422: 888-893 (Apr. 2003).
Hardy Britta
Klapper Leah
Raiter Annat
Carlson Karen Cochrane
CureTech Ltd.
Mor-Research Applications Ltd.
Winston & Strawn LLP
LandOfFree
Peptide useful in immunomodulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide useful in immunomodulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide useful in immunomodulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157316